The Orcoda Ltd (ASX: ODA) share price is one of the few shining lights on the market today. Despite the ASX in a sea of red, Orcado shares are up 40.91% at the time of writing on the back of a contract win.

Despite this rise, however, Orcoda shares are still very much at the smaller end of the ASX spectrum. With shares last changing hands at 15.5 cents, the company’s market capitalisation currently stands at around $18 million.

Orcoda is a logistics solution provider that specialises in business efficiency and optimisation of processes. The company focuses on three key business sectors: healthcare, transportation and resources.

Why is the Orcoda share price defying gravity?

Shortly after the market closed yesterday, Orcoda announced that its subsidiary, Resource Connect Logistics, has signed a nine-year contract with the Mt Buller Ski Resort in Victoria.

The contract comprises a five-year term plus two additional two-year options. Under the arrangement, Resource Connect Logistics will provide guest transit services and rideshare services to Mt Buller Ski Resort customers during the annual ski seasons.

With this, Orcoda will be tasked with ensuring all customers are efficiently moved around the mountain during its seven days a week, two shifts per day operations.

The contract is expected to generate around $2 million to $3 million revenue per annum. And if it runs the full 9-year term, contract revenue value is estimated to be between $20 million and $30 million.

To put these figures into perspective, Orcoda generated $2.4 million revenue in FY19.

The company stated it will be using the technology it has developed for its resource projects and healthcare projects to deliver the Mt Buller project, along with specifically developed platforms for the ski resort.

The company will also work closely with its key supplier Busfleet who supplies Orcoda will all of its buses and drivers.

Management commentary

Commenting on the contract win, Orcoda managing director Geoff Jamieson said:

“Orcoda was awarded this long term contract to provide transport services by the Mt Buller Resort because Orcoda management have a proven history of effectively managing high volume transport requirements, with long term customers, across multiple industries, whilst utilising best in class efficiency and optimization software.”

“COVID-19 restrictions may have an effect on our achievements this ski season but the nature of this agreement should provide long term benefits to the customers of Mt Buller Resort and Orcoda stakeholders,” he added.

More reading

• Should you buy CSL shares before it’s too late?
• Westpac share price lower on AUSTRAC update
• Mach7 share price charges 7% higher on acquisition news
• Tech shares! Should we even invest in anything else?
• Keep a watch on these 3 ASX trends next week

Motley Fool contributor Cathryn Goh has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

The post Orcoda share price rockets 40% on long-term contract win appeared first on Motley Fool Australia.

from Motley Fool Australia https://ift.tt/30BcdCm

The CSL share price is currently trading 16.7% below its all-time high of $342.75. As we have seen recently, many quality shares that have been sold-off can surge in an unstoppable rally on the turn of a dime.

With the CSL share price consolidating, is now the time to buy shares in the biotech giant before its too late?

Why is the CSL share price not at all-time highs?

The fact that CSL is trading below its all-time highs could reflect portfolio rotation among many investors. With the broader market performing stronger than expected, many investors will be opting to take their profits and sell blue-chips like CSL. By freeing up capital, investors can then load their portfolio with more beaten-down laggards and other cyclical shares.

In addition to portfolio rotation, some investors might be selling their CSL shares as the company faces rising collection costs during the coronavirus pandemic.

How has CSL performed during the pandemic?

Although CSL is not actively participating in the race to develop a vaccine for COVID-19, the biotech giant is working to develop potential therapies by collecting plasma from recovered patients. In conjunction with other global biotech companies, CSL has launched a campaign in the US encouraging recovered COVID-19 patients to donate plasma. CSL is also collecting recovered donor plasma in Australia, with the company partnering with the Australian Red Cross Lifeblood Service.

There have been some concerns that the global shutdowns as a result of the pandemic may result in a supply shortage in plasma collection. In addition, CSL has the obligation to ensure the safety of its donors by undertaking various disinfecting and screening protocols, which could impact margins.  

Bullish broker note

Earlier this month, analysts from broker UBS released a bullish note on CSL and slapped a $342 12-month price target on the company. Analysts flagged a 15% decline in plasma collection volume for the April–June period, however volumes are expected to recover as US states move to ease regulations. Researchers from the broker continue to see CSL as the preferred option in the health sector based on the company’s robust product pipeline and low level of gearing.

Should you buy?

In my experience, the fear of missing out, especially in unprecedented times such as this, can cloud the decision making of the most experienced investor. However, in the case of a quality company such as CSL, the decision should be straightforward. This market darling has a strong capital position with more than $1 billion in available liquidity and has also reaffirmed its profit guidance for FY20.

If portfolio rotation is the cause for a drop in CSL’s share price, I think that it won’t be sustained for too long and buyers should flood in again. For more cautious investors it may be prudent to wait until August when CSL reports its full-year results to get a better picture of where the company stands.

More reading

• Top brokers name 3 ASX 200 shares to buy today
• Where to invest $5,000 into ASX 200 shares immediately
• Is the CSL share price in the buy zone?
• 3 companies with great intangible asset moats
• Why CSL, Harvey Norman, IPH, & Saracen shares are charging higher

Nikhil Gangaram has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. owns shares of CSL Ltd. The Motley Fool Australia has no position in any of the stocks mentioned. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

The post Should you buy CSL shares before it’s too late? appeared first on Motley Fool Australia.

from Motley Fool Australia https://ift.tt/3cRsJQZ

The big four banks have all tumbled lower today after they followed the lead of their U.S. counterparts.

The worst performer in the group has been the Westpac Banking Corp (ASX: WBC) share price.

The shares of Australia’s oldest bank were down as much as 6% at one stage. They have since recovered somewhat, but are still down almost 4% to $17.80 at the time of writing.

Why is the Westpac share price sinking lower?

As well as getting caught up in a selloff which has been triggered by concerns over a potential second wave of COVID-19 in the United States, an update by Westpac could be adding to the selling pressure.

Earlier today, Westpac provided an update on its dealings with AUSTRAC. This is in relation to the civil proceedings the agency launched against the bank in November. This was for the alleged contraventions of its obligations under the Anti-Money Laundering and Counter-Terrorism Financing Act.

According to the release, Westpac has continued to review its processes and as part of that has disclosed to AUSTRAC issues regarding its obligation to file threshold transaction reports.

In addition to this, a month after the civil proceedings were launched, as part of Westpac’s lookback announced in its response to AUSTRAC’s claim, Westpac reported additional suspicious matter reports (SMRs) in relation to potential child exploitation.

This morning the bank revealed that AUSTRAC is further investigating these matters and has advised that it may amend its statement of claim to include allegations arising from these investigations.

AUSTRAC has requested further information from the bank on these matters. This includes the details of 272 of its customers, many of whom were subject to SMRs previously.

A further case management hearing is scheduled for next week. Management intends to provide further updates on the matter when appropriate.

More reading

• ASX 200 down 2.2%: Westpac tumbles, TPG reveals special dividend plans
• Why Jumbo, Santos, Westpac, & Zip Co shares are crashing lower
• ASX 200: improved consumer sentiment to near pre COVID-19 levels
• ASX 200 drops 3%, Webjet share price sinks
• What today’s ASX 200 selloff tells me

Motley Fool contributor James Mickleboro owns shares of Westpac Banking. The Motley Fool Australia has no position in any of the stocks mentioned. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

The post Westpac share price lower on AUSTRAC update appeared first on Motley Fool Australia.

from Motley Fool Australia https://ift.tt/2UCPguB